《復牌公告》中核國際(02302.HK)達成所有復牌條件 明覆牌
中核國際(02302.HK)公佈,公司所有復牌條件均已達成,包括對問題進行適當的獨立審查,評估對公司業務經營和財務狀況的影響,公佈調查結果並採取適當的補救措施;進行獨立的內部監控審查並證明公司已實施充分的內部監控和程式;根據《上市規則》規定刊發所有尚未公佈的財務業績,並處理任何審計修訂問題;證明公司遵守《上市規則》第13.24條有關足夠的業務運作及資產,以保證其股份繼續上市的情況等共五項。
公司股份交易自去年4月30日起暫停。鑑於所有復牌指引均已達成,公司已向聯交所申請股份於明日(18日)早上9時起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.